why choose us

First received: June 09, 2023

Clinical Trial: Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Non-Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Pilot Window of Opportunity Study Evaluating Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy Followed by Evaluation of Durvalumab (MEDI4736) in Combination With Platinum Doub

Brief Summary: Non-Small Cell Lung Cancer (NSCLC) is one of the deadliest types of cancer.In lung cancer patients with a tumor that can be removed by surgery, adjuvant chemotherapy increases survival.Neoadjuvant therapy may have advantages such as, it may be more tolerable prior to surgery, earlier treatment may be more efficacious, and it can provide an indication of treatment response.Neoadjuvant treatment can provide pre- and post-treatment specimens for correlative analysis to better understand mechanisms of action and…

Read more